SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to its strategic partnership with Palantir and World View to develop AI-enabled multi-domain intelligence and defense systems, a move seen as highly transformative by the community alongside recent defense tech acquisitions. While many investors are bullish on the company's long-term potential and anticipate a short squeeze, others are expressing concerns over share dilution and the stock's struggle to maintain gains.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare (IXHL) is experiencing a notable rally driven by impending NASDAQ compliance and heightened speculation regarding positive FDA End-of-Phase 2 results for its Fast Track designated sleep apnea drug, IHL-42X, with its low share float further amplifying short squeeze potential among traders.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is actively discussed following multiple strategic announcements, including a sovereign AI architecture with NVIDIA and expanded partnerships in defense, energy, and commercial AI. The community is highly enthusiastic, viewing these collaborations as strong validation of Palantir's AI platform and its crucial role across diverse, high-stakes sectors.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending after reporting a beat on earnings and achieving its first GAAP profitable year, complemented by a new $500M share buyback; however, its conservative forward guidance and subsequent analyst downgrades have fueled a community debate between bullish long-term conviction in agentic AI leadership and concerns over decelerating growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending after securing pivotal Japanese marketing approval for its Alpha DaRT technology, a massive de-risking event that has analysts raising price targets while the community asserts these valuations are still significantly undervalued given the company's strong cash position and promising oncology pipeline.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending due to a new development agreement with Tower Semiconductor to integrate its electro-optic polymer modulators into Tower's silicon photonics platform. The market views this as significant validation, fueling discussions about its role in future AI infrastructure and the long-term potential of its technology, despite ongoing volatility and profit-taking.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following the successful launch of its Alpha Flight 7 mission, which delivered a Lockheed Martin payload into orbit, marking a crucial comeback for the Alpha rocket program and driving positive community sentiment in the competitive commercial space sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending due to escalating tanker attacks and critical supply disruptions in the Strait of Hormuz, driving strong community debate over whether substantial strategic reserve releases can mitigate the sustained geopolitical risk or if oil prices are poised for further significant volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community, fueled by strong conviction, relentlessly promotes the token's "OG Meme" status and authenticity as a Solana-based project, aiming for significant market cap expansion. The community emphasizes consistent engagement and 'bagworking' while encouraging others to join and avoid "fake" tokens.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is trending following its robust earnings report, which surpassed expectations and included upbeat fiscal guidance and significant expansion plans. The community is split, with some questioning the immediate market reaction despite the strong results, while others highlight its appeal as a value-driven retailer benefiting from cautious consumer spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up

Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to advance a Phase 3 program in metabolic dysfunction-associated...

Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference

Altimmune (NASDAQ:ALT) executives used a presentation at the Citizens Life Sciences Conference to outline recent clinical results and development plans for pemvidutide, the company's lead drug...

Altimmune (NASDAQ:ALT) CEO Jerome Benedict Durso Buys 20,000 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Benedict Durso acquired 20,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was bought at an average price...

Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory Weaver acquired 5,000 shares of the company's stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an...

Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Benedict Durso acquired 20,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was acquired at an average...

Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of Altimmune from a "hold" rating to a "sell" rating in a research report on Saturday...

Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial

B. Riley Financial decreased their target price on shares of Altimmune from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Friday...

Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The...

Altimmune Q4 Earnings Call Highlights

Altimmune (NASDAQ:ALT) executives used the company's year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated...

<ul class="summary-bullets"><li>The company said that it had cash and cash equivalents of $340 million as of the end of February, which it deems sufficient to provide an operating runaway into 2028.&nbsp;</li><li>Altimmune has already agreed with the U.S. Food and Drug Administration on an upcoming MASH trial’s design.</li><li>Meanwhile, data from the company’s mid-stage trial of pemvidutide in Alcohol Use Disorder AUD is expected in the third quarter of 2026.</li></ul>Shares of Altimmune Inc (ALT) fell 9% on Thursday after the company reported a wider-than-expected fourth quarter loss.For Q4, the biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial">reported </a>a net loss of $0.27 per share, compared to a net loss of $0.33 in the same period of 2024, but more than a Wall Street estimate of $0.24 per share.<h2 class="st-heading-2">Cash Position</h2>Altimmune said that it had cash and cash equivalents of $340 million as of the end of February, which it deems sufficient to provide an operating runaway into 2028 based on its current expectations for the timing of its late-stage trial in Metabolic Dysfunction-Associated Steatohepatitis.“Our intent is on having the cash resources necessary to execute the MASH phase 3 trial. We'll continue to be strategic and opportunistic in our approach to securing access to the forecasted capital needed to fund the phase 3, and we'll keep you updated on our progress,” CFO Greg Weaver said.Altimmune has already agreed with the U.S. Food and Drug Administration on the upcoming trial’s design. The global late-stage trial of pemvidutide in MASH is expected to evaluate multiple doses of the drug over a 52-week treatment period with biopsy-based endpoints to support potential accelerated approval.Meanwhile, data from the company’s mid-stage trial of pemvidutide in Alcohol Use Disorder AUD is expected in the third quarter of 2026. Pemvidutide is Altimmune’s lead candidate and has also been studied in the treatment of alcohol-associated liver disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.A Stocktwits user said they are buying the dip.<stembedurl>https://www.stocktwits.com/Corpkcots/message/646685890</stembedurl>Another user expressed disappointment over the earnings but voiced hopes for a buyout deal or partnership agreement for the company.<stembedurl>https://www.stocktwits.com/Damnthisappilosthistory/message/646685060</stembedurl>Yet another said that the company has a roadmap in place and is positioning itself for bigger opportunities ahead. “Short-term drops like this do not change the company’s long-term strategy,” they said.<stembedurl>https://www.stocktwits.com/Oziboz/message/646681100</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-ceo-david-ellison-says-wbd-deal-positions-it-to-compete-more-effectively-globally-report/cZdQDDQRI3k">Paramount Skydance CEO David Ellison Says WBD Deal Positions It To Compete More Effectively Globally: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Equity

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.


Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Traders are actively speculating about an imminent partnership or buyout, citing "active and open" management discussions and strategic meetings with banks for Pemvi's future.

Persistent allegations suggest institutional manipulation, with users highlighting entities like Goldman Sachs actively depressing the stock price to benefit from short positions.

Debates intensify over potential shareholder dilution through ATM share increases versus securing non-dilutive funding to support the expensive global Phase 3 MASH trial.

Investors are seeking clarity on the European Medicines Agency (EMA) alignment for the global MASH Phase 3 trial, with conflicting interpretations from recent Jefferies notes and company statements.

User sentiment is divided, with some expressing frustration over repeated information and vague timelines during recent investor conferences, while others highlight increased company exposure.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.24	--	--	N/A
Q4 '25	-$0.23	-$0.27	-15.38%	MISSED
Q3 '25	-$0.27	-$0.21	22.83%	BEAT
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ALT News

ALTAltimmune Inc